Secretin

At a glance

Overview

ChiRhoStim supplies synthetic human secretin, a hormone normally involved in the response to acidic intestinal contents. Its diagnostic value comes from provoking a measurable pancreatic or gastrin response. The product can assist pancreatic exocrine-function assessment, gastrinoma evaluation and identification of the ampulla or accessory papilla during ERCP. These uses depend on technique and clinical context. The current label cautions that medicines and underlying conditions can blunt or exaggerate responses, so an abnormal result should not be interpreted without understanding how the test was prepared, performed and measured.

Supporting sources [1]

How it works

Secretin stimulates pancreatic duct cells to release bicarbonate-rich fluid, helping neutralize acidic contents entering the intestine. Receptor signaling opens pathways including CFTR-mediated secretion, with neural contributions also described. In gastrinoma, an abnormal gastrin response can become a diagnostic signal. The hormone therefore acts as a controlled physiologic stimulus; the measurement and interpretation, not lasting hormone replacement, are the purpose of the approved procedure.

Supporting sources [1]

Approved diagnostic applications

The label covers stimulation of pancreatic secretion to aid diagnosis of exocrine dysfunction, stimulation of gastrin to aid gastrinoma diagnosis, and pancreatic secretion to help locate duct openings during ERCP.

Supporting sources [1]

Technique is part of the test

Label-described studies compared synthetic and biologically derived secretin preparations and assessed pancreatic responses. The label notes variation between investigators and laboratories, so reference values and operator proficiency matter to interpretation.

Supporting sources [1]

Adverse effects observed during testing

In the label-described open-label trial of 531 patients, reported reactions included nausea, vomiting, flushing and upset stomach. Most patients received a single administration. These observations characterize diagnostic exposure and do not establish the safety of repeated administration for unapproved therapeutic purposes.

Supporting sources [1]

Medication-related diagnostic errors

Anticholinergic medicines can blunt pancreatic response. Proton-pump inhibitors and H2 blockers can alter gastrin responses and falsely suggest gastrinoma. Test preparation should follow the supervising clinician’s plan rather than unsupervised withdrawal of necessary medicines.

Supporting sources [1]

Underlying disease can distort response

Prior vagotomy or inflammatory bowel disease can reduce responses, while alcoholic or other liver disease may increase pancreatic secretion enough to mask coexisting pancreatic disease. Additional clinical assessment can therefore be necessary even after a technically completed test.

Supporting sources [1]

Diagnostic secretion is not pancreatic replacement

Secretin briefly stimulates a response for measurement or visualization. It does not supply digestive enzymes, restore destroyed pancreatic tissue or establish treatment for chronic abdominal symptoms. Those clinical goals require separate evidence and evaluation.

Supporting sources [1]